Clinical Trial Update: A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and immunogenicity of different formulations of a meningococcal ACWY vaccine in healthy adults aged 18-40; study completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infection

Drugs mentioned

• GSK3536820A (GSK3536820A meningococcal ACWY conjugate vaccine formulation)
• Menveo (meningococcal group A, C, W-135 and Y conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 2 | Status: COMPLETED | Results posted: 2021-02-09